Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Drug Makers See Benefits In U.S. Obama Administration

This article was originally published in PharmAsia News

Executive Summary

India's pharmas view the newly inaugurated Barack Obama administration in the United States as a good sign for their generics-dominated industry. The country already is the fourth largest generics supplier in the United States, which itself is the world's largest market at $33 billion a year. Indian firms are counting on Obama's promises to cut health care costs, in part by allowing importation of U.S.-approved drugs from other countries and an added emphasis on government coverage of generic versions. Indian pharmaceuticals also look forward to government efforts to remove obstacles they feel branded companies have managed to get put into place, including anti-tariff hurdles. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069883

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel